CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.28B, above the global median of $1.15B
- FinancialsAltman Z-Score 0.96: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.28BUSDvs all stocks (USD)
Revenue (TTM)
427.68MUSDvs all stocks (USD)
Profit Margin
-13.58%vs Biotechnology peers
Beta
0.6050xvs all stocks
52-Week Change
17.65%vs all stocks
Market Capitalization
1.28BUSDvs all stocks (USD)
Enterprise Value
1.28BUSDvs all stocks (USD)
Forward P/E
10.10xvs Biotechnology peers
Price to Sales (TTM)
3.00xvs Biotechnology peers
Price to Book (MRQ)
8.64xvs Biotechnology peers
Enterprise to Revenue
2.99xvs Biotechnology peers
Enterprise to EBITDA
-37.61xvs Biotechnology peers
Gross Margin
94.91%vs Biotechnology peers
Profit Margin
-13.58%vs Biotechnology peers
Operating Margin
-34.71%vs Biotechnology peers
Return on Assets (TTM)
-5.11%vs Biotechnology peers
Return on Equity (TTM)
-39.46%vs Biotechnology peers
Revenue (TTM)
427.68MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.76USDUpdated Jul 18, 2026Quarterly Revenue Growth
27.50%vs Biotechnology peers
Gross Profit (TTM)
318.86MUSDvs all stocks (USD)
EBITDA (TTM)
-34.05MUSDvs all stocks (USD)
Net Income (TTM)
-58.06MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
27.47%vs Biotechnology peers
Operating Cash Flow (TTM)
-36.26MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
86.38KUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
407.32MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
39.54MUSDFY2025 · Dec 31, 2025Gross Profit
367.78MUSDFY2025 · Dec 31, 2025Operating Income
-40.98MUSDvs all stocks (USD)
Pre-tax Income
-60.63MUSDFY2025 · Dec 31, 2025Income Tax Expense
969.00KUSDFY2025 · Dec 31, 2025Net Income
-61.60MUSDFY2025 · Dec 31, 2025EBIT
-32.23MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-29.17MUSDFY2025 · Dec 31, 2025Research & Development
71.53MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
337.23MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
28.40MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.2600USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.2600USDFY2025 · Dec 31, 2025Basic Shares Outstanding
241.03MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
241.03MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-61.60MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-58.80MUSDFY2025 · Dec 31, 2025Free Cash Flow
-60.29MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
68.00MUSDFY2025 · Dec 31, 2025Income Tax Paid
485.00KUSDFY2025 · Dec 31, 2025Interest Paid
15.72MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-61.60MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.06MUSDFY2025 · Dec 31, 2025Stock-based Compensation
48.96MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-1.55MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-14.14MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.23MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-36.76MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.49MUSDFY2025 · Dec 31, 2025Purchase of Investments
-218.92MUSDFY2025 · Dec 31, 2025Sale of Investments
211.46MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-8.96MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
48.67MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
48.67MUSDFY2025 · Dec 31, 2025Shares Outstanding
246.97MSharesUpdated Jul 18, 2026Float Shares
219.78MSharesUpdated Jul 18, 2026Shares Short
25.37MSharesUpdated Jul 18, 2026Short Ratio
5.41daysvs all stocks
Short % of Shares Outstanding
10.50%vs all stocks
% Held by Insiders
3.28%vs all stocks
% Held by Institutions
70.76%vs all stocks
Total Cash (MRQ)
238.07MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.9640USDUpdated Jul 18, 2026Total Debt (MRQ)
234.13MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.58xvs Biotechnology peers
Current Ratio (MRQ)
3.48xvs Biotechnology peers
Book Value per Share (MRQ)
0.6020USDUpdated Jul 18, 2026Total Assets
501.60MUSDvs all stocks (USD)
Total Current Assets
382.32MUSDFY2025 · Dec 31, 2025Total Liabilities
334.65MUSDFY2025 · Dec 31, 2025Total Non-current Assets
119.29MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
246.05MUSDFY2025 · Dec 31, 2025Total Current Liabilities
88.61MUSDFY2025 · Dec 31, 2025Cash
18.57MUSDFY2025 · Dec 31, 2025Cash Equivalents
49.43MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
68.00MUSDFY2025 · Dec 31, 2025Other Short-term Investments
196.69MUSDFY2025 · Dec 31, 2025Accounts Receivable
71.85MUSDFY2025 · Dec 31, 2025Inventory
17.73MUSDFY2025 · Dec 31, 2025Accounts Payable
19.23MUSDFY2025 · Dec 31, 2025Short-term Debt
1.48MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.21MUSDFY2025 · Dec 31, 2025Other Current Liabilities
7.35MUSDFY2025 · Dec 31, 2025Long-term Debt
206.47MUSDFY2025 · Dec 31, 2025Common Stock (Book)
24.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-946.94MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
166.95MUSDvs all stocks (USD)
52-Week Low
4.08USDUpdated Jul 18, 202652-Week High
8.40USDUpdated Jul 18, 202652-Week Change
17.65%vs all stocks
Beta
0.6050xvs all stocks
50-Day MA
5.83USDUpdated Jul 18, 2026200-Day MA
6.04USDUpdated Jul 18, 2026Avg 10-Day Volume
3.02MSharesUpdated Jul 18, 2026Avg 30-Day Volume
4.22MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.2400USDUpdated Jul 18, 2026Other Income / Expense
8.74MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.95Profit Margin: -0.14
Significant cash reserves alongside high leverageNotable
Cash (USD): 238,074,000Total Debt (USD): 234,128,000Debt-to-Equity: 1.58
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.48Altman Z-Score: 0.96
Financial Health
Altman Z-Score 0.96: distress zoneCritical
Altman Z-Score: 0.96
High structural barrier to entryNotable
Barrier to Entry: 11.24
Consistent revenue growth patternNotable
Growth Consistency Score: 0.79
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.28B, above the global median of $1.15BNotable
Market cap (USD): 1,284,552,812Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Sinonep-Allsino Bio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inhibrx Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Liaoning Chengda Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Celltrion Pharm, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bio-Thera Solutions Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Hisun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xencor Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tianjin Ringpu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jade Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Chipotle Mexican Grill, Inc.
1 interpretationRevenue Growing With Receivables Growing
Copart Inc.
1 interpretationRevenue Growing With Receivables Growing
Hangzhou Todaytec Digital Co., Ltd.
1 interpretationRevenue Growing With Receivables Growing